CompletedPhase 1NCT02432235
Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma
Studying Non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ADC Therapeutics S.A.
- Principal Investigator
- Jens Wuerthner, MD, PhDADC Therapeutics
- Intervention
- Camidanlumab tesirine(drug)
- Enrollment
- 133 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2019
Study locations (12)
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
- The University of Texas/MD Anderson Cancer Center, Houston, Texas, United States
- Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
- Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
- Froedtert Hospital/Medical College of Wisconsin, Milwaukee, Wisconsin, United States
- Guy's and St. Thomas' Hospital NHS Trust, London, England, United Kingdom
- The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom
- Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, England, United Kingdom
- The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom
- Southampton General Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02432235 on ClinicalTrials.govOther trials for Non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07222631SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomasUniversity of California, San Diego
- RECRUITINGNCT07313943PAX5-NEGATIVE HODGKIN-LIKE LYMPHOMAS: A DIAGNOSTIC CHALLANGEIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE2NCT07283822Amping up With PemJAKSeda S. Tolu
- RECRUITINGNANCT06923397Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND TrialDana-Farber Cancer Institute
- RECRUITINGPHASE2NCT06854003BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell LymphomaChristine Ryan
- ACTIVE NOT RECRUITINGPHASE1NCT06622226A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin LymphomaOno Pharmaceutical Co. Ltd
- RECRUITINGPHASE1NCT06522932PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T TherapyMichael Randall
- RECRUITINGPHASE1NCT06420089CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)Vittoria Biotherapeutics